What is HC Wainwright’s Forecast for STOK FY2026 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued on Monday, November 2nd. HC Wainwright analyst A. Ghosh now expects that the company will earn ($3.93) per share for the year, down from their prior forecast of ($3.35). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2026 earnings at ($1.11) EPS, Q1 2027 earnings at ($1.10) EPS, Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.85) EPS, FY2027 earnings at ($3.98) EPS and FY2028 earnings at ($1.74) EPS.

STOK has been the subject of a number of other research reports. Canaccord Genuity Group decreased their target price on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. The Goldman Sachs Group restated a “buy” rating and issued a $43.00 price target on shares of Stoke Therapeutics in a report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price objective for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $44.17.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $26.99 on Wednesday. The business has a 50-day moving average of $27.21 and a two-hundred day moving average of $30.85. Stoke Therapeutics has a 12 month low of $20.32 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). Stoke Therapeutics had a negative net margin of 862.07% and a negative return on equity of 66.76%. The firm had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.21 million.

Insider Activity

In related news, insider Barry Ticho sold 1,051 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the transaction, the insider directly owned 19,059 shares of the company’s stock, valued at approximately $498,583.44. The trade was a 5.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel owned 21,225 shares of the company’s stock, valued at approximately $679,836.75. This represents a 11.88% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 27,418 shares of company stock worth $860,914. 9.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc boosted its stake in shares of Stoke Therapeutics by 22.6% in the second quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock valued at $64,000 after purchasing an additional 359 shares during the period. First Trust Advisors LP increased its stake in Stoke Therapeutics by 0.5% during the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock worth $5,322,000 after buying an additional 780 shares during the period. Quantbot Technologies LP purchased a new stake in Stoke Therapeutics during the 2nd quarter worth $34,000. KBC Group NV acquired a new position in Stoke Therapeutics in the 1st quarter worth $36,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Stoke Therapeutics by 195.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after buying an additional 1,215 shares in the last quarter.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2028 EPS forecast slightly, to a loss of $1.74 per share from a loss of $1.78. MarketBeat
• Neutral Sentiment: Stoke announced upcoming investor-conference presentations in November; the notice provides no specific new financial or clinical information. Conference announcement
• Neutral Sentiment: The company’s Q3 2026 earnings-call presentation was posted, but the supplied article entry does not include details that indicate a fresh market-moving development. Q3 results presentation
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $3.93 from $3.35 and its FY2027 estimate to a loss of $3.98 from $2.55. It also lowered its Q4 2026 forecast to a loss of $1.11 per share from $0.81, implying greater expected losses and potentially weighing on sentiment. MarketBeat
• Negative Sentiment: The analyst also trimmed long-term estimates for FY2029 EPS to $1.51 from $1.55 and FY2030 EPS to $3.48 from $3.56, tempering the longer-term earnings outlook. MarketBeat

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.